



Mercury Healthcare Pvt. Ltd., India

Product Name: OKUMA CREAM

Strength: DICLOFENAC DIETHYLAMINE, LINSEED OIL, METHYL SALICYLATE & MENTHOL CREAM

Module I: Administrative Information.

1.3 Product Information

1.3.1 Summary of Product Characteristics (SmPC)

Enclosed.



Mercury Healthcare Pvt. Ltd., India

Product Name: OKUMA CREAM

Strength: DICLOFENAC DIETHYLAMINE, LINSEED OIL, METHYL SALICYLATE & MENTHOL CREAM

Module I: Administrative Information.

1. NAME OF THE MEDICINAL PRODUCT

OKUMA CREAM

1.1 (Trade) name of product

Diclofenac Diethylamine, Linseed Oil, Methyl Salicylate & Menthol Cream

1.2 Strength

Label Claim:

Diclofenac Diethylamine BP

Eq. to Diclofenac sodium.....1.16 % w/w

Linseed oil BP.....1.0 % w/w

Methyl salicylate BP.....10.0 %w/w

Menthol BP.....5.0 %w/w

Cream base.....q.s.

1.3 Dosage Form

Semi-Solid dosage form.

2. QUALITATIVE & QUANTITATIVE COMPOSITION

2.1 Qualitative Declaration

Label Claim:

Diclofenac Diethylamine BP

Eq. to Diclofenac sodium.....1.16 % w/w

Linseed oil BP.....1.0 % w/w

Methyl salicylate BP.....10.0 %w/w

Menthol BP.....5.0 %w/w

Cream base.....q.s.



Mercury Healthcare Pvt. Ltd., India

Product Name: OKUMA CREAM

Strength: DICLOFENAC DIETHYLAMINE, LINSEED OIL, METHYL SALICYLATE & MENTHOL CREAM

Module I: Administrative Information.

2.2 Quantitative Declaration

Batch Size: 100.0 kg

Sr. No.		Specification	Qty. in Kg	O.A. in %	Qty. in Kg
1	Diclofenac Diethylamine	BP	1.160	-	1.218
2	Linseed oil	BP	3.000	5.0	3.000
3	Methyl salicylate	BP	10.00	-	10.00
4	Menthol	BP	5.000	-	5.000
5	White petroleum Jelly	BP	3.300	-	3.300
6	Light liquid paraffin	BP	2.500	-	2.500
7	Cetostearyl Alcohol	BP	5.000	-	5.000
8	Ceto Macrogol-1000	IHs	5.000	-	5.000
9	Carbopol-934	USP	1.000	-	1.000
10	Propylene glycol	BP	10.00	-	10.00
11	Benzyl Alcohol	BP	1.000	-	1.000

3. PHARMACEUTICAL DOSAGE FORM

For topical administration.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

For the local symptomatic relief of pain and inflammation in:

- Trauma of the tendons, ligaments, muscles and joints, eg due to sprains, strains and bruises
- localised forms of soft tissue rheumatism



Mercury Healthcare Pvt. Ltd., India

Product Name: OKUMA CREAM

Strength: DICLOFENAC DIETHYLAMINE, LINSEED OIL, METHYL SALICYLATE & MENTHOL CREAM

Module I: Administrative Information.

It is recommended that the treatment be reviewed after 14 days in these indications. For the treatment of osteoarthritis of superficial joints such as the knee. In the treatment of osteoarthritis, therapy should be reviewed after 4 weeks.

4.2 Posology and method of administration

Adults: Okuma cream should be rubbed gently into the skin. Depending on the size of the affected site to be treated 2-4g (a circular shaped mass approximately 2.0-2.5cm in diameter) should be applied 3 - 4 times a daily.

After application, the hands should be washed unless they are the site being treated.

Use in the elderly: The usual adult dosage may be used.

Children and adolescents: There are insufficient data on efficacy and safety available for the children and adolescents below 14 years of age (see also contraindications section 4.3). In children aged 14 years and over, if this product is required for more than 7 days for pain relief or if the symptoms worsen the patient/parents of the adolescent is/are advised to consult a doctor.

Okuma cream is suitable for the transmission of ultrasound and may be used as a couplant in combination with ultrasound therapy. If large areas of the body are covered with cream, systemic absorption will be greater and the risk of side-effects increased, especially if the therapy is used frequently.

4.3 Contraindications

Patients with or without chronic asthma in whom attacks of asthma, urticaria or acute rhinitis are precipitated by acetylsalicylic acid (aspirin) or other non-steroidal anti-inflammatory drugs (NSAIDs).

- Hypersensitivity to diclofenac or any of the excipients
- Third trimester of pregnancy.
- The use in children and adolescents aged less than 14 years is contraindicated.

4.4 Special warnings and precautions for use



Mercury Healthcare Pvt. Ltd., India

Product Name: OKUMA CREAM

Strength: DICLOFENAC DIETHYLAMINE, LINSEED OIL, METHYL SALICYLATE & MENTHOL CREAM

Module I: Administrative Information.

The possibility of systemic adverse events from application of Okuma cream cannot be excluded if the preparation is used on large areas of skin and over a prolonged period (see the product information on systemic forms of diclofenac).

Okuma cream contains propylene glycol, which may cause mild, localised skin irritation in some people. Concomitant use of oral NSAID's should be cautioned as the incidence of untoward effects, particularly systemic side effects, may increase.

Okuma cream should not be co-administered with other products containing diclofenac.

Okuma cream should be applied only to intact, non-diseased skin and not to skin wounds or open injuries. It should not be allowed to come into contact with the eyes or mucous membranes, and should not be ingested.

Discontinue the treatment if a skin rash develops after applying the product.

Okuma cream can be used with non-occlusive bandages but should not be used with an airtight occlusive dressing.

Some possibility of gastro-intestinal bleeding in those with a significant history of this condition has been reported in isolated cases.

Instruct patients not to smoke or go near naked flames - risk of severe burns. Fabric (clothing, bedding, dressings etc.) that has been in contact with this product burns more easily and is a serious fire hazard. Washing clothing and bedding may reduce product build-up but not totally remove it.

4.5 Interaction with other medicinal products and other forms of interaction

Since systemic absorption of diclofenac from a topical application is very low such interactions are very unlikely. There are no known interactions with Okuma cream but for a list of interactions known with oral diclofenac the data sheet for oral dosage forms should be consulted.

4.6 Fertility, pregnancy and lactation

Pregnancy



Mercury Healthcare Pvt. Ltd., India

Product Name: OKUMA CREAM

Strength: DICLOFENAC DIETHYLAMINE, LINSEED OIL, METHYL SALICYLATE & MENTHOL CREAM

Module I: Administrative Information.

The systemic concentration of diclofenac is lower after topical administration, compared to oral formulations. With reference to experience from treatment with NSAIDs with systemic uptake, the following is recommended:

Inhibition of prostaglandin synthesis may adversely affect the pregnancy and/or the embryo/fetal development. Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk for cardiovascular malformation was increased from less than 1%, up to approximately 1.5 %. The risk is believed to increase with dose and duration of therapy. In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre- and post-implantation loss and embryo-fatal lethality. In addition, increased incidences of various malformations, including cardiovascular, have been reported in animals given a prostaglandin synthesis inhibitor during the organogenesis period. During the first and second trimester of pregnancy, diclofenac should not be given unless clearly necessary. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low and duration of treatment as short as possible.

During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the foetus to:

- Cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension);
- Renal dysfunction, which may progress to renal failure with oligo-hydroamniosis;

The mother and the neonate, at the end of pregnancy, to:

- Possible prolongation of bleeding time, an anti-aggregating effect which may occur even at very low doses.
- Inhibition of uterine contractions resulting in delayed or prolonged labour.

Consequently, diclofenac is contraindicated during the third trimester of pregnancy.

Lactation

Like other NSAIDs, diclofenac passes into breast milk in small amounts. However, at therapeutic doses of Okuma cream no effects on the suckling child are anticipated. Because of a lack of controlled studies in lactating women, the product should only be used during lactation under advice from a healthcare professional. Under this circumstance, Okuma cream should not be applied on the breasts of nursing mothers, nor do elsewhere on large areas of skin or for a prolonged period of time.



Mercury Healthcare Pvt. Ltd., India

Product Name: OKUMA CREAM

Strength: DICLOFENAC DIETHYLAMINE, LINSEED OIL, METHYL SALICYLATE & MENTHOL CREAM

Module I: Administrative Information.

4.7 Effects on ability to drive and use machines

Cutaneous application of Okuma cream has no influence on the ability to drive and use machines.

4.8 Undesirable effects

Adverse reactions (Table 1) are ranked under heading of frequency, the most frequent first, using the following convention: very common ($> 1/10$); common $\geq (1/100, < 1/10)$; uncommon $\geq (1/1,000, < 1/100)$; rare ($\geq 1/10,000, < 1/1,000$); very rare ($< 1/10,000$), not known: cannot be estimated from the available data.

Table 1

<u>Immune system disorder:</u>	
Very rare:	Hypersensitivity (including urticaria), angioneurotic oedema.
<u>Infections and infestations:</u>	
Very rare:	Rash pustular.
<u>Respiratory, thoracic and mediastinal disorders</u>	
Very rare:	Asthma.
<u>Skin and subcutaneous tissue disorders</u>	
Common:	Rash, eczema, erythema, dermatitis (including dermatitis contact), <u>pruritus</u>
Rare:	Dermatitis bullous
Very rare:	Photosensitivity reaction

Although less likely with the topical administration, some side effects normally associated with systemically administered diclofenac may also occur.

4.9 Overdose

Signs and symptoms

The low systemic absorption of Okuma cream renders overdose very unlikely. However, undesirable effects, similar to those observed following an overdose of diclofenac tablets, can be expected if Okuma cream is



Mercury Healthcare Pvt. Ltd., India

Product Name: OKUMA CREAM

Strength: DICLOFENAC DIETHYLAMINE, LINSEED OIL, METHYL SALICYLATE & MENTHOL CREAM

Module I: Administrative Information.

inadvertently ingested (1 tube of 100g contains the equivalent of 1000mg of diclofenac sodium). In the event of accidental ingestion, resulting in significant systemic adverse effects, general therapeutic measures normally adopted to treat poisoning with non-steroidal anti-inflammatory medicines should be used. Gastric decontamination and the use of activated charcoal should be considered, especially within a short time of ingestion

Treatment

Management of over dosage with NSAIDs essentially consists of supportive and symptomatic measures. There is no typical clinical picture resulting from Voltarol overdose. Supportive and symptomatic treatment should be given for complications such as hypotension, renal failure, convulsions, gastro-intestinal irritation, and respiratory depression; specific therapies such as forced diuresis, dialysis or haemoperfusion are probably of no help in eliminating NSAIDs due to their high rate of protein binding and extensive metabolism.

5. Pharmacological properties

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Topical products for joint and muscular pain, anti-inflammatory preparations, non-steroids for topical use (ATC code M02A A15)

Okuma cream is a non-steroidal anti-inflammatory (NSAID) and analgesic preparation designed for external application. Due to an aqueous-alcoholic base the cream exerts a soothing and cooling effect.

Mechanism of Action of Methyl salicylate

Methyl salicylate is a rubefacient. It produces reddening of the skin by dilatation of the blood vessel and gives a soothing feeling of warmth. It is also called as counterirritant because they produce their action by counter irritation. Irritation of the sensory nerve endings alters pain in the underlying muscle or joints that are served by the same nerves.

Mechanism of Action of Menthol



Mercury Healthcare Pvt. Ltd., India

Product Name: OKUMA CREAM

Strength: DICLOFENAC DIETHYLAMINE, LINSEED OIL, METHYL SALICYLATE & MENTHOL CREAM

Module I: Administrative Information.

Menthol acts as a local anesthetic on the respiratory passageways and causing cough suppression. When Menthol is rubbed on the skin, it acts as a rubefacient and causes localized vasodilatation; which gives feelings of comfort and warmth. When applied gently on the skin, it acts as an anti-pruritic agent and creates a feeling of coolness, and mild local anaesthetic effect relieves itching. It has good soothing effect and acts as a demulcent. It also acts as a carminative.

5.2 Pharmacokinetic properties

When Okuma cream is applied locally, the active substance is absorbed through the skin. In healthy volunteers approximately 6% of the dose applied is absorbed, as determined by urinary excretion of diclofenac and its hydroxylated metabolites. Findings in patients confirm that diclofenac penetrates inflamed areas following local application of Okuma cream.

After topical administration of Okuma cream to hand and knee joints diclofenac can be measured in plasma, synovial tissue and synovial fluid. Maximum plasma concentrations of diclofenac are about 100 times lower than after oral administration of Voltarol.

5.3 Preclinical safety data

None known.

6. Pharmaceutical particulars

6.1 List of excipients

White petroleum jelly, Light liquid paraffin,
Cetostearyl Alcohol, Cetomacrogol 1000,
Carbopol-934, Propylene glycol & Benzyl Alcohol.

6.2 Incompatibilities: Not Applicable.

6.3 Shelf life: 36 months.



Mercury Healthcare Pvt. Ltd., India

Product Name: OKUMA CREAM

Strength: DICLOFENAC DIETHYLAMINE, LINSEED OIL, METHYL SALICYLATE & MENTHOL CREAM

Module I: Administrative Information.

6.4 Special precautions for storage

Store upright. Do not store above 25°C.

Do not refrigerate or freeze

6.5 Nature and contents of container

30g cream packed in the liquor coated aluminum tube and each tube is packed in the printed mono carton with insert.

6.6 Special precautions for disposal and other handling

No special requirements for disposal. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. Marketed By:

Mercury Healthcare Pvt. Ltd.,
4, Khaitan Chambers, 2nd Floor,
143-145, Modi Street, Fort, Mumbai,
Maharashtra 400001

Manufactured By

Lesanto Laboratories

Plot no 9, 10 11 & 21, Survey no 53,
Palghar, 401 404, Maharashtra, India